Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
暂无分享,去创建一个
V. Hasselblad | M. Pfeffer | R. Califf | E. Braunwald | H. White | D. Ardissino | J. D. de Lemos | D. Bilheimer | K. Fox | S. Snapinn | F. Verheugt | E. Lewis | L. Gardner | M. Blazing | P. Dibattiste | J. Palmisano | K. Ramsey | Peter M Dibattiste
[1] D. Richman,et al. HIV superinfection. , 2005, The Journal of infectious diseases.
[2] R. Shafer,et al. Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. , 2003, The Journal of infectious diseases.
[3] J. Ornato. Management of patients with unstable angina and non-ST-segment elevation myocardial infarction: update ACC/AHA guidelines. , 2003, The American journal of emergency medicine.
[4] D. Richman,et al. Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus , 2003, AIDS.
[5] Myrna E. Watanabe. Skeptical scientists skewer VaxGen statistics , 2003, Nature Medicine.
[6] P. Armstrong,et al. Randomized Evaluation of the Safety and Efficacy of Enoxaparin Versus Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Receiving the Glycoprotein IIb/IIIa Inhibitor Eptifibatide , 2003 .
[7] G. Specchia,et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2002, European heart journal.
[8] Carl J Pepine,et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.
[9] H. White,et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study☆☆☆★ , 2002 .
[10] GlYcoprotein IIb,et al. The SYNERGY trial: study design and rationale. , 2002, American heart journal.
[11] E. Antman,et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. , 2002, European heart journal.
[12] R. Califf,et al. The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. , 2001, American heart journal.
[13] E. Antman,et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. , 2000, Journal of the American College of Cardiology.
[14] E. Antman,et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.
[15] R H Lyles,et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. , 2000, The Journal of infectious diseases.
[16] H. White,et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban , 1999, The Lancet.
[17] E. Antman,et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.
[18] E. Antman,et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. , 1999, Circulation.
[19] P Théroux,et al. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. , 1998, Circulation.
[20] A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. , 1998, The New England journal of medicine.
[21] Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. , 1998, The New England journal of medicine.
[22] T. Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. , 1997, Circulation.
[23] R. Califf,et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. , 1997 .
[24] J. Hirsh,et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. , 1995, The New England journal of medicine.
[25] K. Mann,et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.